PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma

In head and neck squamous cell carcinoma (HNSCC), data from studies using checkpoint-inhibiting antibodies that target programmed death 1 (PD-1) or its ligand the programmed death ligand 1 (PD-L1) demonstrated outstanding clinical activity. Translational investigations also suggested some correlatio...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology 2020-01, Vol.9 (1), p.1844403-1844403
Main Authors: Evrard, D., Hourseau, M., Couvelard, A., Paradis, V., Gauthier, H., Raymond, E., Halimi, C., Barry, B., Faivre, S.
Format: Article
Language:English
Subjects:
anti-PD-1/PD-L1
biomarkers
Head and neck squamous cell carcinoma
immune checkpoint inhibitors
Review
tumor microenvironment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In head and neck squamous cell carcinoma (HNSCC), data from studies using checkpoint-inhibiting antibodies that target programmed death 1 (PD-1) or its ligand the programmed death ligand 1 (PD-L1) demonstrated outstanding clinical activity. Translational investigations also suggested some correlations between therapeutic response and PD-L1 expression in tumor tissue. We comprehensively summarize results that have evaluated PD-L1 expression in HNSCC. We discuss flaws and strength of current PD-1/PD-L1 detection, quantification methods and the evaluation of PD-L1 as a prognostic and theragnostic biomarker. Understanding tumor microenvironment may help understanding resistance to checkpoint inhibitors, designing clinical trials that can exploit drug combinations.
ISSN:2162-402X
2162-4011
2162-402X
DOI:10.1080/2162402X.2020.1844403